The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

IGF-LR3

Research chemical · Grade C

Goals
healing, muscle, hormonal
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
injectable-sc, injectable-im
WADA
S2
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
the 20-30 hour half-life meant once-daily dosing
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

AOD-9604

Research chemical · Grade C

Goals
weight-loss, muscle, hormonal
Evidence
6 RCT / 4 animal / 3 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Enclomiphene

Off-label · Grade C

Goals
hormonal, libido, muscle
Evidence
4 RCT / 1 animal / 2 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
short plasma half-life (estimated ~10-12 hours in humans under repeated dosing)
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

HGH / Somatropin

FDA-approved · Grade C

Goals
muscle, healing, sleep, weight-loss
Evidence
10 RCT / 3 animal / 2 in vitro
Routes
injectable-sc, injectable-im
WADA
S2
FDA
Approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →